| scholarly article | Q13442814 |
| P50 | author | Ralph A. DeFronzo | Q58689309 |
| P2093 | author name string | M A Abdul-Ghani | |
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria | Q28211392 | ||
| Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095 | Q28346436 | ||
| SGLT2 inhibitors in the treatment of type 2 diabetes | Q30457872 | ||
| Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans | Q33356608 | ||
| Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients | Q33451134 | ||
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
| Discovery of non-glucoside SGLT2 inhibitors | Q34170318 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. | Q34237007 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
| Standards of medical care in diabetes--2007. | Q34595288 | ||
| Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 | ||
| Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 | ||
| Kidney function in early diabetes: the tubular hypothesis of glomerular filtration | Q35600696 | ||
| Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat | Q35950244 | ||
| Phlorizin: a review | Q35995949 | ||
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
| Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial | Q37106527 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes | Q37193454 | ||
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q37278239 | ||
| Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial | Q37302078 | ||
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 | ||
| Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control | Q37351709 | ||
| Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study | Q37532069 | ||
| Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Q37679893 | ||
| Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes | Q37692849 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
| SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
| Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus | Q38005020 | ||
| Diabetes and infection: is there a link?--A mini-review. | Q38062723 | ||
| Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes | Q38164682 | ||
| Is glycemic control improving in U.S. adults? | Q40164421 | ||
| THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN. | Q40978294 | ||
| Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 | ||
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q42706050 | ||
| Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight | Q43046356 | ||
| In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans | Q43227334 | ||
| Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats | Q43644419 | ||
| Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 | ||
| Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes | Q45348074 | ||
| Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus | Q46171591 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial | Q47909934 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. | Q51329266 | ||
| Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. | Q51333570 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 | ||
| Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. | Q51610546 | ||
| Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Q51748822 | ||
| Glucose toxicity | Q68519957 | ||
| Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs | Q69490075 | ||
| Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group | Q71801740 | ||
| Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats | Q72324013 | ||
| Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption | Q73253331 | ||
| Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats | Q73430341 | ||
| Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats | Q73556905 | ||
| Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Q83764954 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Glucose | Q37525 |
| glycobiology | Q899224 | ||
| P304 | page(s) | 352-363 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport | |
| P478 | volume | 276 |
| Q57816534 | 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus |
| Q26800313 | A Call for Systematic Research on Solute Carriers |
| Q28082331 | Adverse effects and safety of SGLT-2 inhibitors |
| Q26741082 | Cardiovascular safety of anti-diabetic drugs |
| Q28075848 | Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond |
| Q26749281 | Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes |
| Q92406528 | Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice |
| Q38802437 | Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. |
| Q28080114 | Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure |
| Q37310483 | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. |
| Q28552106 | Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time |
| Q39093857 | Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. |
| Q94355638 | Long‐term mono‐ or dual‐combination empagliflozin treatment for adults with type 2 diabetes mellitus |
| Q47862649 | Molecular cloning of glucose transporter 1 in grouper Epinephelus coioides and effects of an acute hyperglycemia stress on its expression and glucose tolerance |
| Q38737540 | Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). |
| Q38775305 | SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. |
| Q93173024 | SGLT2 inhibition to address the unmet needs in diabetic nephropathy |
| Q38250445 | Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease |
| Q38783203 | Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes |
| Q41481904 | THE EFFECTS OF Syzygium aromaticum-DERIVED TRITERPENES ON GASTROINTESTINAL GHRELIN EXPRESSION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS. |
| Q39017610 | Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. |
| Q49269658 | The Metabolic Syndrome and Its Components in African-American Women: Emerging Trends and Implications |
| Q47130640 | The NLPR3 inflammasome and obesity-related kidney disease. |
| Q53826483 | The effects of transdermal insulin treatment of streptozotocin-induced diabetic rats on kidney function and renal expression of glucose transporters. |
| Q37632127 | The renal effects of SGLT2 inhibitors and a mini-review of the literature |
| Q38580783 | The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. |
| Q38906041 | Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus |
Search more.